Cover photo
National Institute of Arthritis and Musculoskeletal and Skin Diseases
291 followers|181,065 views


Tenemos información confiable del #NIAMS en audio. ¡Puede escuchar y aprender sobre distintos temas de #salud dondequiera que este! Descárguela ahora.
 ·  Translate
Add a comment...
NIAMS researchers are investigating the potential of using tofacitinib (a drug developed to treat #rheumatoid arthritis) to treat #lupus. Watch as Dr. Massimo Gadina discusses preliminary studies in mice that show promise:

The study was published in “Arthritis and Rheumatology,” the journal of the American College of Rheumatology.

To view the video on YouTube: 
Add a comment...
NIAMS funding helped establish the Research Registry for #lupus. The purpose of the registry is to connect people with lupus with researchers studying this disease. Share If you know someone who might benefit from participating.
Add a comment...
La #vasculitis incluye varias enfermedades que causan #inflamación en los vasos sanguíneos. La #inflamación puede causar problemas graves y las complicaciones dependen de cuáles vasos sanguíneos, órganos u otros sistemas corporales estén afectados. Aprenda más
 ·  Translate
Add a comment...
NIAMS Spotlight on Research: Sex-Differences in #Achilles Tendon Properties May Explain Why Ruptures Occur More Often in Men This study in mice was funded by NIAMS, the NIH National Center for Advancing Translational Sciences and the National Science Foundation and was published in the Annals of Biomedical Engineering. Image credit Louis J. Soslowsky, Ph.D., University of Pennsylvania.
Add a comment...
It's Friday the 13th! But bone health isn't a matter of luck. You can take steps to increase your bone health and reduce your risk of #osteoporosis. Find out here:
Add a comment...
The NIAMS Update comes out next Thursday, January 19. Sign up now to receive it in your email:
Add a comment...
NIAMS Spotlight on Research: Engineered T Cells Alleviate #Autoimmune Skin Disease in Mice. Researchers at the University of Pennsylvania engineered T cells to destroy antibody-producing cells in a mouse model of #pemphigus.
National Institute of Arthritis and Musculoskeletal and Skin Diseases's profile photo
Funding was also provided by the National Cancer Institute and the National Heart, Lung and Blood Institute. In the image, disease-causing antibodies (red) levels are lessened by treatment with engineered T cells [left hand panel] compared to controls [right hand panel] in mucous membrane samples taken from mice with a form of pemphigus vulgaris. Credit: Aimee S. Payne, M.D., Ph.D., and Michael C. Milone, M.D., Ph.D., University of Pennsylvania School of Medicine.
Add a comment...
Congratulations to NIAMS grantee Dawn Cornelison of the University of Missouri, a recipient of a 2017 Presidential Early Career Award for Scientists and Engineers (PECASE)! PECASE is the highest honor bestowed by the United States Government on science and engineering professionals in the early stages of their independent research careers. Read the White House press release here:
Add a comment...
National Institute of Arthritis and Musculoskeletal and Skin Diseases
The mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of the U.S. Department of Health and Human Services' National Institutes of Health, is to support research into the causes, treatment and prevention of arthritis and musculoskeletal and skin diseases; the training of basic and clinical scientists to carry out this research; and the dissemination of information on research progress in these diseases. 

NIAMS Google Plus (G+) Policies

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) participates in this open forum to increase government transparency, enhance information sharing, promote public participation, and encourage collaboration with the U.S. Department of Health and Human Services (HHS), the National Institutes of Health, and the NIAMS.

The NIAMS reserves the right to monitor all postings to its G+ page. Where commenting is supported on this or any other websites owned or administered by the NIAMS, we encourage you to share your thoughts as they relate to the topic being discussed. We reserve the right to remove comments that are inconsistent with our policy, at our discretion.

We will consider your comments when posting new updates, but we are unable to respond directly to individual inquiries. We are also unable to answer questions about your specific health care situation.

The views expressed in comments reflect those of the author and do not necessarily reflect the official views of the NIAMS, the National Institutes of Health (NIH), the U.S. Department of Health and Human Services, or the Federal Government.

Comments that contain the following will be deleted:

  • Political endorsements of parties, candidates, or groups
  • Commercial endorsements of products, services, organizations, or other entities
  • Content that infringes on copyrights
  • Comments on any ongoing investigation of any sort
  • Discriminatory, racist, abusive, obscene, inflammatory, unlawful, or otherwise objectionable statements, language, or content
  • Solicitations of funds
  • Procurement-sensitive information related to any current/future NIAMS acquisitions

We welcome your comments at any time. However, given the need to manage Government resources responsibly, we will review comments during regular business hours, Monday through Friday. Comments submitted on weekends or holidays will be reviewed on the next business day.

Reporters are asked to send questions to the NIAMS Office of Science Policy, Planning and Communications (OSPPC) rather than submitting questions here as comments. Contact the OSPPC at 301-496-8190 or by email to

We reserve the right to block or delete offenders of this policy. We will keep records of all comments that are deleted for the above reasons, as well as those that are posted.


Your Privacy

Remember that your posts are public. When posting, please do not include information (e.g., social security numbers) in the text of your comment that personally identifies you in a way you do not intend. Additional guidance as to how the NIAMS regards privacy issues can be found in our Privacy Statement at

Visitors who become fans or friends of this page, or otherwise use or interact with the site, agree to adhere to the Google+ Policies and  Principles (

Please consider carefully what you choose to post about yourself. You participate at your own risk, taking personal responsibility for your comments. A link to Google’s privacy policy is available at

Linking and Disclaimer of Endorsement

The appearance of external links on this site does not constitute endorsement by the NIAMS, the NIH, or the U.S. Department of Health and Human Services, nor do we endorse the views, products and services they may offer.

We do not guarantee the accuracy, relevance, timeliness, or completeness of information contained on non-NIAMS websites.

We do not guarantee that outside sites comply with Section 508 (Accessibility Requirements) of the Rehabilitation Act.

When you select a link to an outside site, you are leaving this page and are subject to the privacy and security policies of that site.

Contact Information
Contact info
(877) 22-NIAMS
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Information Clearinghouse National Institutes of Health 1 AMS Circle Bethesda, MD 20892-3675